Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-Thrombotic Regimens in Coronary Artery Ectasia
NCT05718531Phase 3Unknown
- Sponsor
- Assiut University
- Start
- Feb 2023
- Primary completion
- Feb 2025
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of rivaroxaban in Coronary artery ectasia (CAE), sponsored by Assiut University. Primary endpoints: Major Adverse Cardiac Events at 1 year and P-selectin marker at 1 year. Status: unknown.
02
Drugs
rivaroxaban
03
Conditions
Coronary artery ectasia (CAE)
Beyond the preview
Go deeper on NCT05718531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05718531.